Malignant neuroleptic syndrome following deep brain stimulation surgery: A case report

被引:12
作者
Themistocleous M.S. [1 ,3 ]
Boviatsis E.J. [1 ,3 ]
Stavrinou L.C. [1 ,3 ]
Stathis P. [2 ]
Sakas D.E. [1 ,3 ]
机构
[1] Department of Neurosurgery, University of Athens Medical School, Evangelismos General Hospital, GR-10676 Athens
[2] Department of Neurology, 1st Hospital of Social Security Services, GR-15127 Athens, Zaimi Str
[3] Hellenic Center for Neurosurgical Research, P.S. Kokkalis, GR-10675 Athens
关键词
Deep Brain Stimulation; Pramipexole; Neuroleptic Malignant Syndrome; Malignant Hyperthermia; Entacapone;
D O I
10.1186/1752-1947-5-255
中图分类号
学科分类号
摘要
Background: The neuroleptic malignant syndrome is an uncommon but dangerous complication characterized by hyperthermia, autonomic dysfunction, altered mental state, hemodynamic dysregulation, elevated serum creatine kinase, and rigor. It is most often caused by an adverse reaction to anti-psychotic drugs or abrupt discontinuation of neuroleptic or anti-parkinsonian agents. To the best of our knowledge, it has never been reported following the common practice of discontinuation of anti-parkinsonian drugs during the pre-operative preparation for deep brain stimulation surgery for Parkinson's disease. Case presentation. We present the first case of neuroleptic malignant syndrome associated with discontinuation of anti-parkinsonian medication prior to deep brain stimulation surgery in a 54-year-old Caucasian man. Conclusion: The characteristic neuroleptic malignant syndrome symptoms can be attributed to other, more common causes associated with deep brain stimulation treatment for Parkinson's disease, thus requiring a high index of clinical suspicion to timely establish the correct diagnosis. As more centers become eligible to perform deep brain stimulation, neurologists and neurosurgeons alike should be aware of this potentially fatal complication. Timely activation of the deep brain stimulation system may be important in accelerating the patient's recovery. © 2011 Themistocleous et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 4 条
[1]  
Adnet P., Lestavel P., Krivosic-Horber R., Neuroleptic malignant syndrome, British Journal of Anaesthesia, 85, 1, pp. 129-135, (2000)
[2]  
Sakas D.E., Kouyialis A.T., Boviatsis E.J., Panourias I.G., Stathis P., Tagaris G., Technical aspects and considerations of deep brain stimulation surgery for movement disorders, Acta Neurochir Suppl, 97, pp. 163-170, (2007)
[3]  
Adnet P.J., Krivosic-Horber R.M., Adamantidis M.M., Haudecoeur G., Adnet-Bonte C.A., Saulnier F., Dupuis B.A., The association between the neuroleptic malignant syndrome and malignant hyperthermia, Acta Anaesthesiologica Scandinavica, 33, 8, pp. 676-680, (1989)
[4]  
Funkiewiez A., Ardouin C., Krack P., Fraix V., Van Blercom N., Xie J., Moro E., Benabid A.-L., Pollak P., Acute psychotropic effects of bilateral subthalamic nucleus stimulation and Levodopa in Parkinson's disease, Movement Disorders, 18, 5, pp. 524-530, (2003)